Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here

Cancer - United States
doi 10.1002/cncr.31272
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Where Do the Immune Checkpoint Inhibitors Stand in the Management of Triple Negative Breast Cancer?

Immunotherapy
OncologyAllergyImmunology
2018English

Where Do We Go From Here?

MRS Bulletin
Materials ScienceTheoretical ChemistryCondensed Matter PhysicsPhysical
1986English

Where Do We Go From Here?

The Philosophers' Magazine
2002English

Where Do We Go From Here?

1989English

Genetic Association Studies of Cancer: Where Do We Go From Here?

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2007English

Dietary Fibre and Colon Cancer: Where Do We Go From Here?

Proceedings of the Nutrition Society
MedicineNutritionDietetics
2003English

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)

Case Reports in Oncological Medicine
Oncology
2019English

Triple-Negative Breast Cancer

2018English

Germline TP53 and MSH6 Mutations Implicated in Sporadic Triple-Negative Breast Cancer (TNBC): A Preliminary Study

Human Genomics
Molecular MedicineDrug DiscoveryGeneticsMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy